Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10234486 | 0.78 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL12968026 | 0.78 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL28067763 | 0.77 | HSD11B1 (0.43) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL482354 | 0.75 | HSD11B1 (0.39) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL19798655 | 0.75 | — | — | |
| SCHEMBL19075611 | 0.74 | — | — | |
| Ammonia Solution, Strong SCHEMBL28328924 | 0.73 | HSD11B1 (0.38) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL12765789 | 0.72 | EPHX2 (0.37) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL12837800 | 0.72 | CYP2C9 (0.39) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL1772242 | 0.72 | CYP2C9 (0.46) | HSD11B1HSD11B2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | HSD11B1 196/4885HSD11B2 127/4885EPHX2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.